Miglitol(CAS:72432-03-2)

Miglitol, CAS number 72432-03-2, is a representative API of second-generation alpha-glucosidase inhibitors. Since its launch, it has long acted as a first-line basic therapeutic raw material for postprandial blood glucose management of type 2 diabetes. With mild efficacy, ultra-low hypoglycemia risk and wide adaptability, it is fully recorded in Chinese Pharmacopoeia, USP and EP. It is widely applied in mass pharmaceutical manufacturing, generic drug development and diabetic pharmacological research. Miglitol appears as white crystalline powder with good water solubility and stable physicochemical properties, resisting degradation under high temperature and conventional storage. Strict control over related substances, heavy metals and residual solvents fully meets industrial standards of oral tablets and international pharmaceutical export specifications, sustaining steady annual market demand.

In terms of pharmacological mechanism, rapid hydrolysis of dietary polysaccharides such as starch and sucrose into glucose catalyzed by intestinal alpha-glucosidase causes sharp blood glucose elevation after meals. After oral administration, Miglitol accumulates on the surface of small intestinal mucosal epithelium, reversibly and competitively binding to the active site of alpha-glucosidase to drastically reduce catalytic efficiency. It slows down the decomposition of complex carbohydrates, extends sugar absorption cycle, avoids drastic postprandial glucose spikes and stabilizes daily glycemic curve. Compared with first-generation acarbose, Miglitol achieves higher intestinal absorption and covers the whole small intestine for more balanced hypoglycemic effect. It barely enters systemic circulation and is excreted via feces in prototype form with minimal metabolic burden on liver and kidneys, enabling standardized administration for patients with mild to moderate renal impairment. Its independent action pathway does not interfere with pancreatic islet function or boost insulin secretion, resulting in almost no hypoglycemia under monotherapy; dosage adjustment is only required when combined with insulin or sulfonylureas, offering a wide safe medication window.

Clinically, Miglitol is indicated for most patients with type 2 diabetes and stands as the preferred API for patients with isolated postprandial hyperglycemia. For newly diagnosed mild type 2 diabetes, monotherapy combined with diet and exercise effectively controls HbA1c and postprandial glucose to slow disease deterioration. For patients with moderately impaired islet function and unsatisfactory glycemic control under long-term metformin treatment, supplementary Miglitol specifically lowers postprandial glucose peaks, narrows day-night glucose difference and reduces risks of vascular complications. It can be safely administered to elderly diabetics, patients with chronic kidney disease and obese diabetic patients without obvious weight gain side effects, balancing glycemic control and weight management. Clinically, it is commonly combined with metformin, DPP4 inhibitors and insulin to build synergistic regimens targeting both fasting and postprandial glucose, serving as an indispensable component for compound antidiabetic preparations.

Regarding industrial production and application, Miglitol adopts mature integrated fermentation and chemical synthesis technology with stable and controllable procedures, uniform batch purity and low impurity limits to support continuous large-scale mass production and consistent supply cycles. The standard oral regimen is taken with three daily meals; mild gastrointestinal adverse reactions gradually subside with extended administration, without severe hepatotoxicity or cumulative toxicity, presenting excellent long-term tolerance. Compared with novel innovative hypoglycemic APIs, Miglitol features moderate production cost, definite curative effect and complete long-term safety data, enjoying huge demand in primary chronic disease medication markets. With rising global prevalence of type 2 diabetes and growing demand for postprandial glycemic control, Miglitol, as a mature and reliable classic antidiabetic API, maintains irreplaceable practical value in generic drug manufacturing, primary care formulation export and basic medical research, sustaining stable and broad long-term development prospects in the global pharmaceutical industry.